NCT01756118 2023-02-16
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Goethe University
Phase 1 Completed
Clinical Trials
18 trialsNCT01482156 2020-12-21
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00620594 2020-12-09
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01634061 2020-12-09
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Novartis
Phase 1 Completed
NCT01495247 2020-12-08
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 1/2 Terminated
NCT01337765 2020-10-09
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
Pfizer
Phase 1 Completed
NCT01856101 2019-04-10
BEZ235
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01658436 2016-05-02
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Novartis
Phase 2 Completed
NCT01628913 2016-04-07
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Novartis
Phase 2 Terminated
NCT01453595 2016-02-29
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT02430363 2016-02-24
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Medical Research Council
Phase 1/2 Unknown
NCT01343498 2015-05-01
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01690871 2013-08-02
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Novartis
Phase 2 Withdrawn
NCT01290406 2012-06-21
BEZ235 Trial in Patients With Advanced Endometrial Carcinoma
Novartis
Phase 2 Withdrawn
NCT01288092 2012-06-07
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
Novartis
Phase 2 Withdrawn